Cargando…

Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy

BACKGROUND: Aim of this study was to compare cancer incidence in populations with and without diabetes by cancer site. Furthermore, we aimed at comparing excess risk of cancer according to diabetes type, diabetes duration and treatment, the latter as regards Type 2 diabetes. METHODS: By use of the R...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballotari, Paola, Vicentini, Massimo, Manicardi, Valeria, Gallo, Marco, Chiatamone Ranieri, Sofia, Greci, Marina, Giorgi Rossi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5657107/
https://www.ncbi.nlm.nih.gov/pubmed/29070034
http://dx.doi.org/10.1186/s12885-017-3696-4
Descripción
Sumario:BACKGROUND: Aim of this study was to compare cancer incidence in populations with and without diabetes by cancer site. Furthermore, we aimed at comparing excess risk of cancer according to diabetes type, diabetes duration and treatment, the latter as regards Type 2 diabetes. METHODS: By use of the Reggio Emilia diabetes registry we classified the resident population aged 20–84 at December 31(st) 2009 into two groups: with and without diabetes. By linking with the cancer registry we calculated the 2010–2013 cancer incidence in both groups. The incidence rate ratios (IRR) by cancer site, type of diabetes, diabetes duration, and as concerns Type 2 diabetes, by treatment regimen were computed using Poisson regression model and non-diabetic group as reference. RESULTS: The cohort included 383,799 subjects without diabetes and 23,358 with diabetes. During follow-up, we identified 1464 cancer cases in subjects with diabetes and 9858 in the remaining population. Overall cancer incidence was higher in subjects with diabetes than in those without diabetes (IRR = 1.22, 95%CI 1.15–1.29), with similar results focusing on subjects with at least 2-year diabetes duration. Cancer sites driving overall increased risk were liver, pancreas, Colon rectum, and bladder in both sexes, corpus uteri for females. There was also suggestion of an increased risk for kidney cancer in females and a decreased risk for prostate cancer. Excess risk was found in patients with Type 2 diabetes, more marked among insulin users, especially with combined therapy. We observed an increasing risk for diabetes duration up to 10 years from diagnosis (IRR = 1.44, 95%CI 1.29–1.61) and a subsequent decrease to moderate-higher risk (IRR = 1.15, 95%CI 1.04–1.30). CONCLUSIONS: Our study indicates that the strength of association depends on specific cancer site. Insulin, monotherapy or combined therapy, per se or as an indication of poor blood glucose control, in addition to diabetes duration, may play a role in the association of diabetes and cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3696-4) contains supplementary material, which is available to authorized users.